Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 16/20 | 0.65 |
| ▸ | PPARA | Q07869 | 7/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16503293 | 1.00 | PPARD (0.65) | PPARDPPARAFFAR1PPARG | |
| SCHEMBL16503302 | 1.00 | PPARD (0.65) | PPARDPPARAFFAR1PPARG | |
| SCHEMBL21870082 | 0.91 | PPARD (0.56) | PPARDPPARAFFAR1PPARG | |
| SCHEMBL14567150 | 0.91 | PPARD (0.56) | PPARDPPARAFFAR1PPARG | |
| SCHEMBL14567147 | 0.90 | PPARD (0.55) | PPARDPPARAFFAR1PPARG | |
| SCHEMBL2356852 | 0.83 | FFAR1 (0.62) | PPARDPPARAFFAR1 | |
| SCHEMBL3948386 | 0.83 | FFAR1 (0.62) | PPARDPPARAFFAR1 | |
| SCHEMBL3021109 | 0.83 | FFAR1 (0.62) | PPARDPPARAFFAR1 | |
| SCHEMBL16077453 | 0.82 | PPARD (0.53) | PPARDPPARAFFAR1PPARG | |
| SCHEMBL13284781 | 0.82 | PPARD (0.53) | PPARDPPARAFFAR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312995-A1 | BRIDGED AND FUSED HETEROCYCLIC ANTIDIABETIC COMPOUNDS | SCHERING CORPORATION (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2007033002-A1 | CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312995-A1 | BRIDGED AND FUSED HETEROCYCLIC ANTIDIABETIC COMPOUNDS | GPR119, FFAR2, FFAR1 | PPARD 28/4885PPARA 50/4885FFAR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.